Veru Inc.

Veru Inc. is an oncology biopharmaceutical company that develops and commercializes medicines for cancer management. Its commercial products include FC2 female condom/internal condom for dual protection against unintended pregnancy and sexually transmitted infections. The company's drug candidates are in various stages of clinical trials, targeting metastatic breast cancer, triple negative breast cancer, metastatic castration and androgen receptor targeting agent resistant prostate cancer, advanced hormone sensitive prostate cancer, hot flashes, and SARS-CoV-2 treatment. Veru Inc. also focuses on advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate.

Products

• FC2 female condom/internal condom

• Enobosarm

• Sabizabulin

• VERU-100

• Zuclomiphene Citrate

• New drug formulation for lower urinary tract symptoms